-
ESMO China Voice | Prof. Jiayu Wang: MAIC Analysis Highlights the Potential of Bireociclib as a Second-Line Therapy for HR+/HER2– Advanced Breast Cancer, Offering a New Treatment Option for Patients
In the second-line treatment of hormone receptor–positive, HER2-negative (HR+/HER2–) advanced breast cancer, CDK4/6 inhibitors combined with fulvestrant have become the standard of care. However, variations in efficacy and safety profiles among different inhibitors remain an important clinical consideration.
-
Prof. Man Li’s Team Reveals CDK12–ERBB2 Co-Amplification Mechanism and Explores a Novel “Metabolism–Repair–Resistance” Pathway
The 2025 European Society for Medical Oncology (ESMO) Annual Congress, held in Berlin, Germany from October 17 to 21, brought together global experts to present cutting-edge advances in cancer research — from basic science to translational breakthroughs and clinical innovation.
-
ESMO Hot Topic | Professor Zhao Yanxia: PATINA Trial PRO Data Confirm Palbociclib Combination Extends PFS Without Compromising Quality of Life
The PATINA (AFT-38) trial is a randomized, open-label, phase III study designed to evaluate the efficacy and safety of palbociclib + HER2-targeted therapy + endocrine therapy versus HER2-targeted therapy + endocrine therapy alone in patients with HR+/HER2+ metastatic breast cancer following induction therapy. Previous data from PATINA demonstrated that the addition of palbociclib significantly prolonged…
-
ESMO Hot Topic | Professor Zhang Juliang: Long-Term GeparNuevo Follow-Up Reveals Durable Survival Benefits from Durvalumab Neoadjuvant Therapy in Early Triple-Negative Breast Cancer
At the 2025 ESMO Annual Congress, the long-term follow-up results of the GeparNuevo trial (Abstract #292MO) were presented. The data showed that although durvalumab combined with neoadjuvant chemotherapy did not significantly improve the pathological complete response (pCR) rate, it significantly prolonged survival outcomes, including invasive disease-free survival (iDFS), distant disease-free survival (DDFS), and overall survival…
-
ESMO Hot Topic | Professor Li Huiping: monarchE Trial OS Results Announced — A New Breakthrough in Adjuvant Therapy for HR+/HER2- High-Risk Early Breast Cancer
At the 2025 ESMO Annual Congress, the overall survival (OS) data from the monarchE trial were released, showing that abemaciclib combined with endocrine therapy significantly improved survival in patients with HR+/HER2- high-risk early breast cancer, reducing the risk of death by 15.8%.
-
ESMO China Voice | Prof. Jian Zhang: SMP-656 Shows Early Promise, Offering New Hope for Patients Resistant to HER2 ADC Therapy
Editor’s Note: With its remarkable therapeutic efficacy, DS-8201 has dramatically reshaped the treatment landscape for patients with advanced breast cancer. In HER2-positive advanced breast cancer, DS-8201 has firmly established its…
-
Bridging the World, Shaping the Future | 2025 CRHA Conference on Frontiers in Cell Therapy and Biomedicine Opens in Xiong’an
Editor’s Note: In the golden season of autumn, leading experts gathered in the City of the Future to discuss the frontiers of cell therapy. On October 31, 2025, the 2025…
-
Focusing on the Frontier, Gathering Wisdom in Xiong’an | 2025 CRHA Conference on Cell Therapy and Biomedical Frontiers Opens Grandly
Editor’s Note: As autumn brings its golden harvest, scientific progress likewise flourishes. The 2025 Chinese Research Hospital Association Conference on Cell Therapy and Biomedical Frontiers, jointly organized by the Cell…
Connecting Medical Expertise through Media